[中图分类号] R979.1[文献标识码] A[文章编号] 1000-1530(2000)04-0354-04
The anti-tumor effect of murine EL-4 tumor cells transfected
with both of B7 and IL-6 gene
HAO Jie
(Department of Immunology, Peking University, Beijing100083, China)
BO Xiao-Zhen
(Department of Immunology, Peking University, Beijing100083, China)
XIE Shu-Sheng
(Department of Immunology, Peking University, Beijing100083, China)
ABSTRACTObjective: To explore whether co-expression of IL-6 and B7 in EL-4 tumor cells could initiate an synergistic antitumor effect.Methods: The retroviral vectors pLmB7SN and pLhIL-6SN were transfected into the packaging cell line CRIP and the virus particles containing IL-6 or B7 gene were used to infect EL-4 tumor cells, obtaining the cell lines EL-4-IL-6, EL-4-B7 and EL-4-IL-6+B7. B6 mice were injected subcutaneously with various EL-4 transfectant cells and tumor growth conditions were observed. The vaccine potency of the above engineered EL-4 variants was analyzed.Results: When mice were immunized with the above irradiated EL-4 transfectant cells and challenged 7 days later with parental EL-4 cells, the survival time of mice was significantly prolonged. However, there is no difference between the survival time of mice vaccination with EL-4 cells transfected with double IL-6+B7 genes and single IL-6 or B7 gene.Conclusion: No synergistic antitumor immunity was observed in double IL-6+B7 genes transfected EL-4 cells.
KEY WORDSTransfection; Vaccines/pharmacol; Interleukin-6; Drug synergin; Thymoma
(J Beijing Med Univ, 2000,32:354-357)
90年代以来人们用转基因肿瘤疫苗在小鼠模型中对其抗肿瘤免疫作用进行了广泛的研究,结果相差甚大[1,2]。IL-6是一种生物学活性广泛的细胞因子,参与细胞毒T细胞的活化,B细胞的分化[3,4]。全身使用高剂量的IL-6能导致小鼠体内的肿瘤消退[5]。B7分子是T细胞表面CD28分子的配体,CD28-B7是T细胞活化的重要信号传导通路。用导入了B7基因的小鼠肿瘤细胞接种小鼠发现,B7分子能够诱导抗肿瘤免疫应答[6]。我们选用小鼠胸腺瘤细胞EL-4作肿瘤模型,构建了带有hIL-6cDNA的逆转录病毒载体,通过逆转录病毒的介导制备了双基因转染的EL-4肿瘤细胞,从致瘤性、抗肿瘤疫苗效应等方面研究B7分子和IL-6双基因转染的肿瘤细胞是否具有增强的抗肿瘤能力。
1材料与方法
试剂:限制性内切酶EcoRI, BamHI及λDNA/HindⅢ+EcoRI购自华美公司;牛肠道碱性磷酸酶CIAP,T4DNA连接酶及Agarose购自Promega;polybrene和MTT购自Sigma;G418和磷酸钙转染药盒购自Gibco;antiCD80-FITC购自Pharmgen;重组人IL-6标准品购自我系分子免疫室。
细菌株及载体:DH5α本室冻存;pBSF2.38,pLXSN和pLmB7SN由我校俞莉章老师惠赠。含IL-6 cDNA的质粒pBSF2.38的构建由日本Osaka大学的Toshio Hirano 等完成。
细胞株与动物:C57BL/6小鼠,6~8周龄,我校实验动物科学部提供。EL-4胸腺瘤细胞株(源于C57BL/6小鼠)、NIH3T3小鼠成纤维细胞株、ψCRIP双向性逆转录病毒包装细胞均为本室冻存;7TD1IL-6依赖株由马大龙教授惠赠。
pLhIL-6SN的构建(图1)及鉴定:EcoRI/BamHI双酶切pBSF2.38及pLXSN载体,用T4DNA连接酶将编码全长hIL-6的cDNA(约1100bp)和用碱性磷酸酶处理的酶切后的pLXSN载体连接起来,连接物转化DH5α感受态细胞,挑选12个克隆提取质粒,用EcoRI,BamHI进行双酶切分析,筛选,确定均为阳性克隆(图2)命名为pLhIL-6XN。基因操作按Ausubel等[8]的方法进行。
图1pLhIL-6SN逆转录病毒载体构建示意图
Figure 1Construction of pLhIL-6SN retrovirus vector
1,pLhIL-6SN; 2,pLXSN/EcoRI+BamHI; 3,pLhIL-6SN/EcoRI+BamHI;
4,pBSF2.38/EcoRI+BamHI; 5,λDNA/EcoRI+HindⅢ.
图2pLhIL-6SN的内切酶鉴定
Figure 2Restriction enzyme analysis of pLhIL-6SN
逆转录病毒的包装:利用磷酸钙转染药盒提供的方法把pLhIL-6SN和pLmB7SN分别转染包装细胞ψCRIP,2~3d后用含200mg.L-1G418的选择培养基筛选阳性克隆,约10~14d可见抗性克隆。
病毒滴度的测定:按文献[7]进行。Titer为(克隆数×病毒上清稀释倍数)/(所用病毒上清体积×加G418时传代比例)。
病毒颗粒感染EL-4细胞:将ψCRIP-IL-6,ψCRIP-B7的细胞培养上清过滤除菌后,按文献[7]的方法感染EL-4细胞。
hIL-6活性及mB7表达的检测:利用IL-6依赖的小鼠杂交瘤细胞系7TD1及MTT法测定IL-6生物活性;FACS检测B7表达。
EL-4-IL-6/B7(EL-4-D)细胞的制备及表达的检测:用ψCRIP-IL-6细胞培养上清感染EL-4-B7细胞,利用依赖株法测定IL-6生物活性。
小鼠荷瘤实验:分别取1×105的EL-4、EL-4-IL-6、EL-4-B7和EL-4-D细胞接种C57BL/6小鼠背部皮下,观察肿瘤结节生长及小鼠存活时间。
疫苗的免疫保护实验:分别取1×106X-射线灭活的EL-4、EL-4-IL-6、EL-4-B7和EL-4-IL-6/B7细胞于小鼠一侧前肢皮下接种免疫,7 d后以1×105的EL-4细胞于小鼠另一侧前肢皮下接种,观察肿瘤结节的生长及小鼠的存活时间。
统计学处理:数据以±s表示。各组小鼠肿瘤结节生长速度的比较采用SAS软件,GLM过程做方差分析。各组小鼠存活期的比较采用Excel软件,做t检验。
2结果
包装细胞病毒滴度测定:分别收获ψCRIP-IL-6,ψCRIP-B7细胞24 h培养上清,感染NIH3T3细胞,检测病毒滴度,结果可见:3株ψCRIP-IL-6的病毒滴度分别为1.1×105、1×105、0.3×105 CFU.ml-1;3株ψCRIP-B7的病毒滴度分别为0.5×103、1.2×103、3×103CFU.ml-1。
pLhIL-6SN基因表达的鉴定:用7TD1IL-6依赖株,MTT法检测0.5×106ml-1培养液EL-4-IL-6细胞24 h上清中的IL-6活性,重组人的IL-6作为标准,做IL-6标准曲线(图3)对照,测得EL-4-IL-6产生hIL-6水平为100U.ml-1, EL-4-IL-6/B7细胞为60 U.ml-1, EL-4产生IL-6的水平为0。
Quasi-liner regression curve formed by least square principle.
The correlation coefficient is -0.987, the slop
is -0.0237 and the intercept is 0.3425.
图3MTT法IL-6标准曲线
